iDayo Selects HALO as Low Risk Investment

Call Now
800-993-0005

(^DJI) 0

0S&P 500 (^GSPC) 1318.86

2.23NASDAQ Composite (^IXIC) 2850.12

11.04Russell 2000 (^RUT) 765.17

5.54

iDayo™ Stock Selector: HALO - Halozyme Therapeutics

iDayo™ 04/16/07: Halozyme Therapeutics (HALO) - 04/16/07

For the 16 week investment period starting 04/16/07 , the iDayo™ Stock Selector rated Halozyme Therapeutics (HALO) as "Extreme Accumulation" and selected HALO as a buy for the investment period, identified as iDayo™ 04/16/07.

Company Profile for "Halozyme Therapeutics (HALO)": Halozyme Therapeutics, Inc., a biopharmaceutical company, engages in the development and commercialization of recombinant human enzymes for the infertility, palliative care, drug delivery, and oncology treatments.

Google Finance History for HALO

iDayo, Inc. (including its marketing professionals and staff), is not a registered Investment Advisor or Broker/Dealer, and does not provide investment advice or recommendations. Subscribers to iDayo™ are advised that the information, opinions, and analysis included in our web sites, on our free Educational Conference Calls, or in any other communication are based in good faith on sources believed to be reliable, but no representation or warranty, expressed or implied, is made as to their accuracy, completeness, or correctness.

Past performance is not necessarily indicative of the future performance of stocks posted. None of these postings, the iDayo™ system rating, nor any other information provided on our web sites, on our free Educational Conference Calls, or in any other communication constitutes a recommendation to buy or sell stocks or any other investment. Investing involves the risk of loss and Subscribers are urged to consult with their own independent financial advisors with respect to any investment.